Top Tech Companies (2,068)
Don't see your company?
Create a company profile
Volumetric is an advanced biomaterials and biofabrication company.
This company is a specialty pharmaceutical company focused on developing innovative drugs.
Headquartered in Brooklyn, New York, Cresilon, Inc. is a privately-held medical device company focused on hemostatic technologies that improve wound care and advance the standard of medical treatments. For more information, visit Cresilon.com. We are always looking for dynamic people to join our team as we dive into a range of challenges at the forefront of science and technology—to learn more about our openings please visit https://cresilon.workable.com/.
Universal Stabilization Technologies is a San Diego-based biopharmaceutical R&D company.
Jenrin Discovery is a biopharmaceutical Company.
EcoGen BioSciences is a producer, manufacturer and supplier of compliant specialty hemp ingredients globally. Our platform of in-house processing and extraction provides innovative bulk and private label service opportunities for our customers. Curated from our processing and extraction facilities, our team has developed a broad range of the highest quality hemp derived cannabinoids and customized formulations for the beverage, food, cosmetics, wellness, and pharmaceutical industries.
ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and a worldwide leader in innovative laboratory research and development. A nonprofit enterprise of the University of Utah, ARUP offers an extensive test menu of highly complex and unique medical tests.
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com. Community Guidelines: http://bit.ly/ArvinasCG
Velia is an emerging biotech harnessing the broad therapeutic potential of a newly identified, yet abundant class of human proteins. Transformational work from Velia founders revealed that many of those previously overlooked proteins regulate biological functions vital to human health. Velia will discover and develop therapeutics targeting these novel regulators.
Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
Oxeia Biopharmaceuticals is a clinical stage biotech company.
HealthPlan Data Solutions, through its fully-owned subsidiary Rx-Xchange, helps patients and caregivers pay less for medications.
WaveFront Dynamics is a medical device company with innovative wavefront diagnostic technology.
Pulmotect develops products that boost the innate immune system to protect against a wide range of lung infections.
Torus Biosystems is developing the next generation of POC molecular diagnostics for syndromic infectious diseases based on the novel integration of qPCR and microarray technologies that enable detection and quantification of DNA in under 30 minutes. The Synestia™ System employs the syndromic testing approach, which is faster and more accurate than conventional methods, and delivers rapid, comprehensive, sample-to-answer solutions at the patient point of care in a compact and portable system that supports decentralized healthcare settings. Torus Biosystems was spun out from the Wyss Institute for Biologically Inspired Engineering at Harvard University in 2020 to develop and commercialize the proprietary DNA/RNA detection technology developed by Wyss Core Faculty member, Peng Yin, PhD, Professor, Department of Systems Biology, Harvard Medical School, and Wyss Alumnus David Zhang, PhD, Associate Professor of Bioengineering, Rice University. Learn more about how Torus Bio can help improve patient outcomes, combat antibiotic resistance, and promote antimicrobial stewardship in a wide range of ambulatory settings including Hospital Outpatient and Emergency Departments and Long-Term Care facilities. Visit the website at www.torus.bio and connect with on social media @Twitter and @LinkedIn.
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com. For view our social media policies, please visit https://agendia.com/legal-compliance/
InfraScan is a medical device company.
We focus on genomic technologies and provide complete solutions for gene profiling and screening for all life science applications. By means of integrating high-throughput laboratory and microarray fabrication facilities, GenoSensor has become a nationwide leading company in bioassay services and development. Our COVID-19 test kit assays 3 target genes unique to SARS-CoV-2 having higher specificity and exhibiting lower risk for mutation. Our kit is simple to use and ready to utilize in all-in-one master mix reagents and controls minimize variability.
Becker Underwood is the global leader in the development & commercialization of value-creating seed-applied biological products.
BioForce Nanosciences, Inc. develops and commercializes nanotech instruments, consumables, and applications for the life sciences.
